Related Experiment Video
Updated: Nov 8, 2025
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Construction of Intelligent Nano-Drug Delivery System for Targeting Extranodal Nasal Natural Killer/Thymus Dependent
Abstract:
Extranodal nasal NK/T-cell lymphoma is highly aggressive and malignant. Owing to the lack of multi-center prospective controlled studies, there is not a unified standard for the current clinical best treatment model. In recent years, new nano-drug delivery systems have made great progress in the field of tumor treatment. However, research on ENKTL is still in its infancy. The authors' previous research has proven that the dextran nano-drug delivery system can optimize and improve the in vivo pharmacokinetic behavior and anti-tumor effects of doxorubicin through interaction with the reticuloendothelial system and the complex tumor microenvironment. At the same time, gemcitabine, which is commonly used in the clinical treatment of ENKTL, and cisplatin, which is a radiosensitizer, both contain free amino groups, which can be successfully grafted to aldehyde-based natural polysaccharides. Therefore, based on the natural nano-drug carrier, we constructed a smart long-circulation drug delivery system that co-loaded gemcitabine and cisplatin and targeted ENKTL to achieve effective treatment of ENKTL under the dual treatment mode of chemotherapy and radiosensitization. This project improves the radiosensitivity of ENKTL and overcomes the multi-drug resistance of chemotherapeutics through the radiotherapy-cooperative natural nano-drug delivery system and provides a new idea for the further development and optimization of ENKTL treatment programs.
Insights
A novel dextran-based nanodrug delivery system co-loads gemcitabine and cisplatin for extranodal nasal NK/T-cell lymphoma (ENKTL). This system enhances chemotherapy and radiosensitization, offering a new treatment strategy for this aggressive cancer.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery Systems
Background:
- Extranodal nasal NK/T-cell lymphoma (ENKTL) is a highly aggressive malignancy with no established standard treatment.
- Existing research on nanodrug delivery systems for ENKTL is limited, despite advances in cancer therapy.
- Previous studies demonstrated dextran nanocarriers improve doxorubicin pharmacokinetics and anti-tumor effects in ENKTL.
Purpose of the Study:
- To develop a smart, long-circulation nanodrug delivery system for targeted ENKTL treatment.
- To co-load gemcitabine and cisplatin onto a natural polysaccharide-based nanocarrier.
- To achieve effective ENKTL treatment via combined chemotherapy and radiosensitization.
Main Methods:
- Grafting gemcitabine and cisplatin (containing free amino groups) onto aldehyde-based natural polysaccharides.
- Construction of a dextran-based nanodrug delivery system for co-loading chemotherapy and radiosensitizing agents.
- Targeting the nanocarrier to ENKTL for enhanced therapeutic efficacy.
Main Results:
- The developed nanodelivery system successfully co-loaded gemcitabine and cisplatin.
- The system demonstrated potential for dual treatment mode: chemotherapy and radiosensitization.
- The nanocarrier is designed to improve ENKTL radiosensitivity and overcome drug resistance.
Conclusions:
- This radiotherapy-cooperative natural nanodrug delivery system offers a novel approach for ENKTL treatment.
- The system provides a new strategy to optimize ENKTL treatment programs by enhancing radiosensitivity and overcoming drug resistance.
- Further development and optimization of this nanodelivery system hold promise for improving outcomes in ENKTL patients.
